Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Chao ZhuZhen ZhouIzanne RoosDaniel MerloTomas KalincikSerkan OzakbasOlga SkibinaJens KuhleSuzanne HodgkinsonCavit BozRaed AlroughaniJeannette Lechner-ScottMichael Harry BarnettGuillermo IzquierdoAlexandre PratDana HorakovaEva Kubala HavrdovaRichard MacdonellFrancesco PattiSamia Joseph KhouryMark SleeRana KarabudakMarco OnofrjVincent Van PeschJulie PrevostMastura MonifVilija G JokubaitisAnneke Van Der WaltHelmut Butzkuevennull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
After fingolimod cessation, ocrelizumab and natalizumab were more effective in reducing relapses than cladribine. Due to the low ARRs in all three treatment groups, additional observation time is required to determine if statistical difference in ARRs results in long-term disability differences.